XML 33 R13.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | NOTE D – GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
| As of December 31, 2021 |  | As of December 31, 2020
(in millions) | Gross Carrying Amount |  | Accumulated Amortization/Write-offs(1) |  | Gross Carrying Amount |  | Accumulated Amortization/Write-offs
Technology-related | $ | 11,957 |  |  | $ | (6,754) |  |  | $ | 11,059 |  |  | $ | (6,179) |
Patents | 494 |  |  | (398) |  |  | 511 |  |  | (407) |
Other intangible assets | 1,900 |  |  | (1,325) |  |  | 1,775 |  |  | (1,220) |
Amortizable intangible assets | $ | 14,351 |  |  | $ | (8,476) |  |  | $ | 13,345 |  |  | $ | (7,806) |
Goodwill | $ | 21,888 |  |  | $ | (9,900) |  |  | $ | 19,924 |  |  | $ | (9,973) |
IPR&D | 126 |  |  |  |  | 257 |  |  |
Technology-related | 120 |  |  |  |  | 120 |  |  |
Indefinite-lived intangible assets | $ | 246 |  |  |  |  | $ | 377 |  |  |
(1) In the fourth quarter of 2020, we recorded goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. The goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business are no longer presented within accumulated write-offs above as of December 31, 2021. Intangible asset impairment charges were $370 million in 2021, $460 million in 2020 and $105 million in 2019. The impairment charges recorded in 2021 were primarily associated with intangible assets established in connection with our acquisition of Millipede, Inc. and VENITI, Inc. The impairment charges recorded in 2020 were primarily associated with intangible assets established in connection with our acquisitions of Sadra Medical, Inc., Apama Medical Inc. and nVision Medical Corporation (nVision). Each of these impairment charges were recorded following management’s decision to cancel the programs due to the length of time, and remaining cost to complete and commercialize the technology, the cost to remediate quality issues or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology. The following represents our goodwill balance by global reportable segment and our separately presented Specialty Pharmaceuticals operating segment:
(in millions) | MedSurg |  | Rhythm and Neuro |  | Cardiovascular |  | Specialty Pharmaceuticals |  | Total
Balance as of December 31, 2019 | $ | 2,061 |  |  | $ | 2,192 |  |  | $ | 5,676 |  |  | $ | 247 |  |  | $ | 10,176 |
Foreign currency fluctuations and other changes | (2) |  |  | 3 |  |  | 22 |  |  | — |  |  | 22 |
Goodwill impairment charges | — |  |  | — |  |  | — |  |  | (73) |  |  | (73) |
Goodwill reclassified to Current assets held for sale | — |  |  | — |  |  | — |  |  | (175) |  |  | (175) |
Balance as of December 31, 2020 | $ | 2,059 |  |  | $ | 2,194 |  |  | $ | 5,697 |  |  | $ | — |  |  | $ | 9,951 |
Foreign currency fluctuations and other changes | (5) |  |  | (1) |  |  | (21) |  |  | — |  |  | (27) |
Goodwill acquired | 544 |  |  | 1,309 |  |  | 210 |  |  | — |  |  | 2,064 |
Balance as of December 31, 2021 | $ | 2,598 |  |  | $ | 3,503 |  |  | $ | 5,887 |  |  | $ | — |  |  | $ | 11,988 |
In 2021, we did not record any Goodwill impairment charges. In 2020, we recorded Goodwill impairment charges of $73 million related to our Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. We did not record any Goodwill impairment charges in 2019. Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing. Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2021 is as follows (in millions):
Fiscal Year |
2022 | $ | 752 |
2023 | 738 |
2024 | 703 |
2025 | 644 |
2026 | 620 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration